HK1010153A1 - Recombinant human alpha-fetoprotein and uses thereof. - Google Patents

Recombinant human alpha-fetoprotein and uses thereof.

Info

Publication number
HK1010153A1
HK1010153A1 HK98111257A HK98111257A HK1010153A1 HK 1010153 A1 HK1010153 A1 HK 1010153A1 HK 98111257 A HK98111257 A HK 98111257A HK 98111257 A HK98111257 A HK 98111257A HK 1010153 A1 HK1010153 A1 HK 1010153A1
Authority
HK
Hong Kong
Prior art keywords
fetoprotein
recombinant human
human alpha
alpha
recombinant
Prior art date
Application number
HK98111257A
Other languages
English (en)
Inventor
Robert A Murgita
Original Assignee
Robert A Murgita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Robert A Murgita filed Critical Robert A Murgita
Publication of HK1010153A1 publication Critical patent/HK1010153A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
HK98111257A 1995-01-24 1998-10-15 Recombinant human alpha-fetoprotein and uses thereof. HK1010153A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37731695A 1995-01-24 1995-01-24
US37731195A 1995-01-24 1995-01-24
US37731795A 1995-01-24 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein
PCT/US1996/000996 WO1996022787A1 (en) 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof

Publications (1)

Publication Number Publication Date
HK1010153A1 true HK1010153A1 (en) 1999-06-17

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98111257A HK1010153A1 (en) 1995-01-24 1998-10-15 Recombinant human alpha-fetoprotein and uses thereof.

Country Status (7)

Country Link
EP (1) EP0805687A4 (de)
JP (2) JPH10513347A (de)
CN (1) CN1150030C (de)
AU (1) AU700975B2 (de)
CA (1) CA2211324C (de)
HK (1) HK1010153A1 (de)
WO (1) WO1996022787A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
WO2001058922A2 (en) * 2000-02-10 2001-08-16 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
EP1958503A3 (de) * 1999-01-06 2008-11-26 Merrimack Pharmaceuticals, Inc. Expression von ausgeschiedenem menschlichen Alpha-Fetoprotein in transgenen Tieren
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
WO2001003501A2 (en) * 1999-07-12 2001-01-18 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
EP1789066A4 (de) * 2004-09-09 2009-10-28 Serometrix Llc Zusammensetzungen und verfahren zur verwendung von alpha-fetoprotein-wachstumshemmungspeptiden
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
CN101743018A (zh) * 2006-12-19 2010-06-16 梅里麦克药品公司 甲胎蛋白和免疫调谐剂的共同施用以治疗多发性硬化
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (zh) * 2016-03-21 2016-07-06 海南医学院 一种获得人类甲胎蛋白的方法
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
EP0356399A3 (de) * 1988-08-26 1991-03-20 Sandoz Ag Substituierte 4-Azatricyclo (22.3.1.04.9) octacos-18-en-Derivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
WO1993005774A1 (en) * 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
DE59509887D1 (de) * 1994-09-26 2002-01-10 Infineon Technologies Ag Koppelanordnung zum optischen aneinanderkoppeln eines oeic-bausteins und optischer fasern

Also Published As

Publication number Publication date
EP0805687A1 (de) 1997-11-12
CA2211324C (en) 2012-07-10
JPH10513347A (ja) 1998-12-22
AU4903596A (en) 1996-08-14
AU700975B2 (en) 1999-01-14
JP2008073041A (ja) 2008-04-03
WO1996022787A1 (en) 1996-08-01
CN1179106A (zh) 1998-04-15
CA2211324A1 (en) 1996-08-01
EP0805687A4 (de) 2000-05-31
CN1150030C (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
IL122428A0 (en) Minizymes and minribozymes and uses thereof
HK1096974A1 (en) Antibody against human parathormone related peptides
HRP970144A2 (en) Human bikunin
EP0790826A4 (de) Dyhydropyrimidine und deren verwendungen
HK1010153A1 (en) Recombinant human alpha-fetoprotein and uses thereof.
EP0768038A3 (de) Backfett unf dessen Verwendung
GB9500601D0 (en) Modified peptides
ZA964825B (en) Collagen peptide fraction and its uses.
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
EP0836617A4 (de) Parevine und tachyteprine
ZA96240B (en) Novel peptides their preparation and use
ZA964862B (en) Optimized minizymes and miniribozymes and uses thereof
EP0828512A4 (de) Box-abhängiges mit myc-interagierendes protein (bin1) aus maus und mensch und seine verwendung
EP1012262A4 (de) Menschliches frezzeled-ähnliches protein
PL324822A1 (en) Human protein mp52 arg
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
GB9423372D0 (en) Proteins and their uses
ZA96239B (en) Novel peptides their preparation and use
EP0744125A3 (de) Jodkomplex und dessen Verwendung
EP0841393A4 (de) Menschliches galectin-4-ähnliches protein und dafür kodierende dna
GB9519865D0 (en) Protein
PL327175A1 (en) Novel peptides, their production and application
GB9622436D0 (en) Protein
EP0857732A4 (de) Menschlicher pec-60-aehnliches protein und dafuer kodierende dna
AU3894497A (en) Novel human glycoprotein

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: RICHARD BOISMENU

PE Patent expired

Effective date: 20160123